Modeling and simulation offer useful predictions that can help guide your drug development program—but what if you could get even more out of the available technology?
In this webinar, presenters President of Simulations Plus John DiBella, DILIsym Services Divisions President Brett Howell and Senior Principal Scientist Jeff Woodhead will discuss how using AI/ML, PBPK, and QSP/QST modeling together can support better decision-making and streamline your entire drug discovery and development process. To illustrate how this can work in real-life scenarios, they’ll share an example from a recent project in which they utilized machine learning, PBPK and pharmacology technologies to predict the liver safety of Verdiperstat ahead of Phase 3 clinical trials. In this webinar, attendees will hear about sponsors’ common project motivations and challenges within their active development programs. They will learn how to directly connect GastroPlus PBPK modeling outputs with the DILIsym platform to produce liver safety predictions that can drive drug development program decisions. Additionally, attendees will have the opportunity to ask questions during the Q&A, moderated by VP of Business Development Josh Fohey.